SEC Tracker
Get the app

Traws Pharma TRAW

Traws Pharma enters $50M stock deal

Item 1.01 Enters material agreement

Form
8-K
Filed
Importance
Major
  1. Enters into a $50M stock purchase agreement with Roth Principal Investments.
  2. Company can sell up to $50M in common stock over 36 months.
  3. Purchase price is 94% of VWAP during market open periods.

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Traws Pharma files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Mannatech MTEX public float $10M, Jun 30, 2025
  2. LeonaBio ATHA public float $10M, Jun 30, 2025
  3. BioCardia BCDA public float $10M, Jun 30, 2025
  4. Alaunos Therapeutics TCRT public float $10M, Jun 30, 2025
  5. Raphael Pharmaceutical RAPH public float $9M, Jun 30, 2025